Company Profile

Maine BioTek Inc
Profile last edited on: 2/27/18      CAGE: 3CQQ4      UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
2002
First Award
2003
Latest Award
2007
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

259 Main Street PO Box 408
Winterport, ME 04496
   (207) 223-4662
   sclouthier@hotmail.com
   www.mainebiotek.com
Location: Single
Congr. District: 02
County: Waldo

Public Profile

Maine Biotek is focused to issues in fish pathology and in their quest for relevant vaccines to address diseases, principals of the firm are working their way through dozens of potential approaches. Once vaccines seems to have potential in the lab, Anderson and Clouthier continue their work at a Canadian government research facility in St. Andrews, New Brunswick. The first few BioTek vaccines to receive approval probably will be produced at an out-of-state facility, but, the hope is to build the sort of sanitary facility needed for vaccine production - both for ISA and a number of other fish diseases that the company is investigating -in Maine

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2007 2 NSF $599,322
Project Title: Atlantic Cod Nodavirus Vaccine
2007 2 DOC $395,000
Project Title: A Multivalent Bacterial Vaccine for Atlantic Cod
2005 2 USDA $371,000
Project Title: Preparation of an IHN Virus Whole Killed Vaccine: Retention of Neutralizing Epitope Integrity of the IHN Virus Glycoprotein During Viral
2004 2 USDA $371,000
Project Title: Recombinant ISA Virus Vaccine
2003 1 NSF $94,376
Project Title: Recombinant Infectious Hematopoietic Necrosis (IHN ) Virus G Protein Vaccine

Key People / Management

  Sharon Clouthier -- President

  Eric Anderson

Company News

There are no news available.